BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19060422)

  • 1. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan.
    Yamashita S; Bujo H; Arai H; Harada-Shiba M; Matsui S; Fukushima M; Saito Y; Kita T; Matsuzawa Y
    J Atheroscler Thromb; 2008 Dec; 15(6):292-303. PubMed ID: 19060422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Where are we with probucol: a new life for an old drug?
    Yamashita S; Matsuzawa Y
    Atherosclerosis; 2009 Nov; 207(1):16-23. PubMed ID: 19457483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma.
    Inazu A; Koizumi J; Kajinami K; Kiyohar T; Chichibu K; Mabuchi H
    Atherosclerosis; 1999 Aug; 145(2):405-13. PubMed ID: 10488970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST).
    Sawayama Y; Shimizu C; Maeda N; Tatsukawa M; Kinukawa N; Koyanagi S; Kashiwagi S; Hayashi J
    J Am Coll Cardiol; 2002 Feb; 39(4):610-6. PubMed ID: 11849859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia.
    Inagaki M; Nakagawa-Toyama Y; Nishida M; Nakatani K; Nakaoka H; Kawase M; Kawase R; Tsubakio-Yamamoto K; Masuda D; Ohama T; Matsuyama A; Ishigami M; Komuro I; Yamashita S
    J Atheroscler Thromb; 2012; 19(7):643-56. PubMed ID: 22785024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of probucol on elderly hypercholesterolemic patients in the FAST study.
    Sawayama Y; Maeda S; Ohnishi H; Okada K; Hayashi J
    Fukuoka Igaku Zasshi; 2006 Jan; 97(1):15-24. PubMed ID: 16613215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis.
    Kasai T; Miyauchi K; Kubota N; Kajimoto K; Amano A; Daida H
    Atherosclerosis; 2012 Feb; 220(2):463-9. PubMed ID: 22024277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prebeta1-HDL levels in hypercholesterolemia are maintained by probucol but reduced by a low-cholesterol diet.
    Miida T; Yamaguchi T; Tsuda T; Okada M
    Atherosclerosis; 1998 May; 138(1):129-34. PubMed ID: 9678778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
    Matsuzawa Y; Yamashita S; Funahashi T; Yamamoto A; Tarui S
    Am J Cardiol; 1988 Jul; 62(3):66B-72B. PubMed ID: 3394656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
    J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for cardiovascular events in Japanese patients treated with fluvastatin from the long-term event monitoring (LEM) study.
    Morishita R; Itakura H; Nakaya N; Yoshida M; Odawara M; Ichihara A; Mizuno K
    Curr Vasc Pharmacol; 2012 Mar; 10(2):178-86. PubMed ID: 21824105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles.
    Helve E; Tikkanen MJ
    Atherosclerosis; 1988 Aug; 72(2-3):189-97. PubMed ID: 3063268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of probucol on hypercholesterolemia in renal transplant patients.
    Okubo M; Nakamura M; Horii A; Kamata K; Takeuchi Y; Tsukamoto Y; Kobayashi N; Sato K; Endo T
    Kidney Int Suppl; 1999 Jul; 71():S229-30. PubMed ID: 10412784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II).
    Pietro DA; Alexander S; Mantell G; Staggers JE; Cook TJ
    Am J Cardiol; 1989 Mar; 63(11):682-6. PubMed ID: 2646895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy.
    Galema-Boers AM; Lenzen MJ; Engelkes SR; Sijbrands EJ; Roeters van Lennep JE
    J Clin Lipidol; 2018; 12(2):409-416. PubMed ID: 29398430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of probucol on homozygous cases of familial hypercholesterolemia.
    Yamamoto A; Matsuzawa Y; Kishino B; Hayashi R; Hirobe K; Kikkawa T
    Atherosclerosis; 1983 Aug; 48(2):157-66. PubMed ID: 6615580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Béliard S; Boccara F; Cariou B; Carrié A; Collet X; Farnier M; Ferrières J; Krempf M; Peretti N; Rabès JP; Varret M; Vimont A; Charrière S; Bruckert E;
    Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated Analysis of Two Probucol Trials for the Secondary Prevention of Atherosclerotic Cardiovascular Events: PROSPECTIVE and IMPACT.
    Arai H; Bujo H; Masuda D; Ishibashi T; Nakagawa S; Tanabe K; Kagimura T; Kang HJ; Kim MH; Sung J; Kim SH; Kim CH; Park JE; Ge J; Oh BH; Kita T; Saito Y; Fukushima M; Matsuzawa Y; Yamashita S
    J Atheroscler Thromb; 2022 Jun; 29(6):850-865. PubMed ID: 33867420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical assessment of probucol and its therapeutical effect on hypercholesterolaemia (author's transl)].
    Herdová J; Zapletalová J
    Cas Lek Cesk; 1981 Jul; 120(27):832-5. PubMed ID: 7261004
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic impact of familial hypercholesterolemia on long-term outcomes in patients undergoing percutaneous coronary intervention.
    Tscharre M; Herman R; Rohla M; Piackova E; Vargas KG; Farhan S; Freynhofer MK; Weiss TW; Huber K
    J Clin Lipidol; 2019; 13(1):115-122. PubMed ID: 30344049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.